Fact Sheet: President Donald J. Trump is Increasing Medical Marijuana and Cannabidiol Research

President Trump signed an Executive Order directing the Attorney General to expedite rescheduling marijuana to Schedule III of the Controlled Substances Act, instructing HHS to develop real‑world evidence research methods for hemp‑derived cannabinoids, and asking the White House to work with Congress on access to full‑spectrum CBD products. The announcement cites HHS findings that 40 states plus DC have medical programs, some 30,000 clinicians recommend marijuana for over six million patients, and FDA recognition of credible support for uses such as anorexia, nausea/vomiting and pain — all of which could broaden research, regulatory clarity and commercial opportunities across cannabis and CBD suppliers. For investors, the move increases the probability of faster clinical research, potential easing of federal restrictions, and greater regulatory certainty that could benefit listed cannabis, CBD product vendors and related healthcare/biotech players, though legislative and implementation risk remains.

Analysis

Market structure: Rescheduling to Schedule III materially reduces regulatory friction for clinical research, banking, and interstate commercial integration—winners are US-focused MSOs (patient channels, labs, CPG manufacturers) and large diversified pharmas that can fund trials and rollups. Expect a 6–18 month window where publicly listed MSOs could gain pricing power in states where medical prescription frameworks are implemented; illicit/fragmented local players and pure-play hemp CBD brands without FDA pathways face margin compression and consolidation.

Risk assessment: Tail risks include judicial reversal, Congressional pushback, or restrictive FDA labeling that preserves high compliance costs; assign 15–25% probability over 12 months to regulatory reversal scenarios that would reprice equities by >40%. Near-term (days–weeks) volatility will spike on headlines; meaningful fundamental benefit likely occurs over 6–24 months as clinical evidence and banking access materialize. Hidden dependencies: banking access, tax (280E) reform, and state-level licensing remain gating factors.

Trade implications: Tactical long exposure to an industry ETF (MJ) and select US MSOs with clean balance sheets should be sized small (2–4% portfolio each), with 12–18 month time horizon; implement call spreads (LEAP 12–18m) to cap cost and target 50–100% upside. Pair trades: long US MSO (Curaleaf CURLF / Trulieve TCNNF) vs short Canada-centric CGC/TLRY to capture re-rating of US operators; rotate into healthcare names (PFE, MRK) that may acquire assets.

Contrarian angles: Consensus assumes rapid de-risking—market may underprice continued friction (banking + 280E). The reschedule improves research BUT does not legalize interstate commerce; expect a multi-year, fragmented rollout giving active managers M&A and consolidation alpha. If clinical trials disappoint or FDA imposes strict labeling, expect a >30% correction in valuations of high-multiple names.

Key Decisions for Investors

• Establish a 2–4% notional long position in MJ (ETFMG Alternative Harvest ETF, ticker MJ) via 12–18 month call spread (buy 12m LEAP 25% OTM call, sell 50% OTM call) to express upside while limiting premium; target +50–100% return, stop loss -25% on premium.
• Initiate a relative-value pair: long Curaleaf (CURLF) 1.5–3% portfolio, short Canopy Growth (CGC) 1.5–3% portfolio, equal $ exposure; hold 6–18 months, target pair return 30–60% if US-focused operators re-rate, cut if regulatory text narrows (monitor 280E, banking guidance within 90 days).
• Buy 6–12 month out-of-the-money call options on select pharma acquirers (PFE or MRK) sized 0.5–1% each as merger arb convexity—these benefit if large pharmas pursue M&A (monitor FDA/HHS guidance and announced trials over next 3–9 months).
• Reduce cyclical exposure in consumer-packaged goods brands that rely on unregulated CBD SKUs by 2–5% and reallocate to healthcare/biotech names working on cannabinoid indications (increase healthcare weight by 2–4%); re-evaluate after initial HHS/FDA implementation (30–90 days).